Vertex plunks down $950M for stem cell player Semma Therapeutics | Fierce Biotech
Vertex gibt Erteilung des Fast-Track-Status durch die FDA und Start der klinischen Phase-1/2-Studie zu VX-880 bekannt – eine neuartige Zelltherapie zur Behandlung von Typ-1-Diabetes | Business Wire
Vertex to buy Semma Therapeutics for $950m in cash
Former Novartis, Magenta exec Bastiano Sanna to lead Cambridge diabetes startup Semma Therapeutics - Boston Business Journal
Creating the next cell therapies for diabetes – Eric Bender
Semma Therapeutics - YouTube
Harvard and Semma Therapeutics improve insulin yield from stem cells
Semma Therapeutics Raises $114 Million for Stem Cell Diabetes Treatment
Semma Therapeutics Announces Pre-Clinical Proof-of-Concept in Two Lead Programs in Type 1 Diabetes | Business Wire
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff | The Motley Fool
Start-up Semma Therapeutics raises 114 million dollars to beat type 1 diabetes - Diabetes
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Semma raises $114 million for Type 1 diabetes treatment
Will Rhode Island Win the Race to Cure Diabetes? - Rhode Island Monthly
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy | Nature Reviews Endocrinology
Hospital Docente SEMMA Santo Domingo - El Día Mundial de la Diabetes es un día de campaña de concienciación acerca de la diabetes y tiene lugar cada año el 14 de noviembre.
Vertex Expanding into Diabetes Cell Therapy with Plans to Acquire Semma
Biotech startup to fight diabetes on the cellular front - The Boston Globe
Harvard diabetes researcher details science behind potential breakthrough – Harvard Gazette
A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
Semma gets $44 million in funding for cell therapy for T1D
Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers | Fierce Biotech
Vertex Targets Type 1 Diabetes Cure with Acquisition of Semma Therapeutics – ISPE Boston
Vertex Bets $950 Million on Stem Cells to Cure Diabetes | Fortune
Semma Therapeutics, Backed by the JDRF T1D Fund, Acquired by Major Biopharma Company - JDRF
Semma Therapeutics Acquired by Vertex Pharmaceuticals for $950M : 2019 Reports : Report Library : Publications : Juvenile Diabetes Cure Alliance (JDCA)
Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes | Business Wire
